The Anticoagulant Mechanism of Action of Recombinant Hirudin (CGP 39393) in Plasma

Summary

We studied the inhibitory action of recombinant desulphatohirudin (CGP 39393) on thrombin generation in whole plasma. Human plasma was activated either with thromboplastin or factor IXa. Hirudin delayed thrombin generation, but it was unable to prevent the explosive appearance of thrombin. The dose-dependent prolongation of the lag phase of the intrinsic and extrinsic thrombin generation curve was not the result of titration of thrombin activity by hirudin but the result of a delayed formation of the prothrombin converting complex (prothrombinase). In case of extrinsic activation, hirudin did not affect factor Xa generation, but prolonged the lag phase of the factor Va generation curve, causing its appearance when factor Xa generation was already in the decay phase. Because of its inhibitory action on the thrombin-mediated activation of factor VIII, hirudin prolonged the lag phase of the factor X converting complex that consists of factor IXa and factor VIIIa. Our observations with hirudin are in keeping with the notion that inhibition of the thrombin-mediated amplification reactions in blood coagulation is a very efficient way to delay or inhibit completely thrombin generation. However, although hirudin neutralizes stoichiometric amounts of thrombin, the interaction between in situ generated thrombin and hirudin appears not to be fast enough to prevent trace amounts of thrombin to activate factors VIII and V. Consequently, an explosive thrombin generation is observed even when free hirudin is present.

• References

• 1 Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 1970; 69: 924-932
• 2 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628
• 3 Grossenbacher H. Information sheet CIBA-GEIGY, released 11-08-88.
• 4 Jackson CM, Nemerson Y. Blood coagulation. Annu Rev Biochem 1980; 49: 765-811
• 5 Rosing J, Thns G, Govers-Riemslag JW P, Zwaal RF A, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-283
• 6 Van Dieijen G, Thns G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42
• 7 Pieters J, Lindhout I, Hemker HC. In situ generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 102l-4
• 8 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemostas 1989; 61: 25-29
• 9 Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton JW, Bldjchman MA. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochem J 1989; 257: 143-150
• 10 Braun PJ, Dennis S, Hofsteenge J, Stone SR. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 1988; 27: 6517-22
• 11 Owren PA, Aas K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 201-218
• 12 Pieters J, Willems G, Hemker HC, Lindhout T. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation. J Biol Chem 1988; 263: 15313-15318
• 13 Schoen R, Lindhout I, Willems G, Hemker HC. Antithrombin IIIdependent anti-prothrombinase activity of heparin and heparin fragments. J Biol Chem 1989; 264: 10002-10007
• 14 Hendrix FI, Lindhout I, Mertens K, Engels W, Hemker HC. Activation of human prothrombin by stoichiometric levels of staphylocoagulase. J Biol Chem 1983; 258: 3637-3644
• 15 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
• 16 Hemker HC, Willems G, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986; 56: 9-17
• 17 Talbot MD, Ambler J, Butler KD, Findlay VS, Mitchell KA, Peters RE, Tweed MF, Wallis RB. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemostas 1989; 61: 77-80
• 18 Hofsteenge J, Thguchi H, Stone SR. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochem J 1986; 237: 243-51
• 19 Pieters J, Lindhout T, Willems G. The heparin-stimulated inhibition of factor IXa generation and factor IXa neutralization in plasma.. Blood 1990; 76: 549-554
• 20 Bdguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1989; 60: 457-62